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Abstract
Serotype replacement has been reported in carriage and disease after pneumococcal conjugate vaccine (PCV) introductions
in the UK and globally. We previously described concurrent expansion and decline of sequence types associated with
serotype replacement over 5 years following PCV introductions in the UK. Here we use whole-genome sequencing to fully
characterise the population structure of pneumococcal isolates collected over seven winters encompassing PCV7 and PCV13
introductions in the UK, investigating the importance of lineages in serotype replacement. We analysed 672 pneumococcal
genomes from colonised children of 4 years old or less. The temporal prevalence of 20 lineages, defined by hierarchical
Bayesian analysis of population structure (BAPS), was assessed in the context of serotype replacement. Multiple serotypes
were detected in the primary winter of sampling within three vaccine-type (VT) lineages BAPS4, BAPS10 and BAPS11, in
which serotype replacement were observed. In contrast, serotype replacement was not seen in the remaining three VT
lineages (BAPS1, BAPS13 and BAPS14), that expressed a single serotype (6B, 6A and 3, respectively) in the primary winter.
One lineage, BAPS1 serotype 6B was undetectable in the population towards the end of the study period. The dynamics of
serotype replacement, in this UK population, was preceded by the presence or absence of multiple serotypes within VT
lineages, in the pre-PCV population. This observation could help predict which non-vaccine types (NVTs) may be involved in
replacement in future PCV introductions here and elsewhere. It could further indicate whether any antibiotic resistance
associated with the lineages is likely to be affected by replacement.
DATA SUMMARY
1. All metadata, phylogeny and ENA accession numbers are
deposited in microreact: https://microreact.org/project/
Southampton-pneumo-carriage.
INTRODUCTION
Streptococcus pneumoniae has been estimated to be respon-
sible for 5,800 hospitalisations annually in England and
Wales before the introductions of pneumococcal conjuga-
tive vaccines (PCVs) [1]. Since the introduction of PCV7 in
2006 and PCV13 in 2010, vaccine serotype replacement had
nearly completed by winter 2012/13; non-vaccine types
account for the majority of carriage pneumococcus isolates
from children aged 4 or less, while the prevalence of naso-
pharyngeal colonisation remained unchanged [2–4]. In con-
trast, the incidence of invasive disease has fallen since then;
disease caused by non-vaccine types (NVTs) did not offset
the reduction in vaccine types (VTs) [5, 6].
We previously reported the expansion of sequence types (STs),
particularly ST432(21) and ST439(23B), in carriage isolates
after the implementation of PCV7; highlighting that clonal
expansion played an important role in serotype replacement in
the UK [3]. To date, only changes in serotype prevalence have
been reported for the additional 2 years post PCV13 imple-
mentation [4]. A single vaccine serotype (VT) can be associ-
ated with multiple different STs and clonal complexes (CCs),
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whichmay influence how replacement will proceed. Therefore,
the role of clonal expansions in serotype replacement war-
ranted further investigation. However, previous studies, which
only reported multi-locus sequence type (MLST) data (repre-
senting <0.2% of the pneumococcal genome), have limited
resolution to fully resolve key relationships within a clone in
the pneumococcal population. A clonal complex is defined as
STs that share six or more of the seven loci with other STs in
the complex, however a single base pair mutation results in a
new ST allele. A clonal complex is also limited by the necessity
for complete sampling of the connective, single-locus variant,
network used to infer relatedness, even in the context of the
public databases. Robustly defining lineages beyond ST using
higher resolution techniques would allow a detailed analysis of
population structure after PCV introductions.
It has been reported that vaccine escape occurring within line-
ages is a result of selection for existing pneumococci express-
ing NVT capsules. These variants have been reported to be
generated via historical, pre-PCV, capsular switch events [7,
8]. Therefore, we proposed the hypothesis that detection of
existing NVT variants in established lineages prior to PCV
introduction could be predictive for serotype replacement.
Whilst serotypes included in PCVs were selected on the basis
of their association with disease, some of the dominant line-
ages expressing VTs were also associated with high levels of
antibiotic resistance. Therefore, assessing indications for line-
ages being replaced or reduced in the population, could also
be predictive of the maintenance through replacement or
reduction in antibiotic resistance in these lineages. Addition-
ally the ability of pneumococci to exchange genetic material
through homologous recombination varies between lineages
and plays a role in both capsular switch variants and the
spread of antibiotic resistance [7, 9].
We sought to fully resolve the population structure beyond
ST, into discrete lineages for this UK carriage collection. We
define the major lineages and relate this to serotype replace-
ment, recombination and prevalence of antibiotic resistance
determinants over PCV introductions.
METHODS
Nasopharyngeal swabs were collected from children aged
4 years old or less during seven consecutive winters (Octo-
ber–March) from 2006/7 to 2012/13. The sample collection
methodology has been previously reported [3, 10, 11] and
approved by UK NHS Research Ethics (06/Q1704/105).
Approximately 100 isolates of S. pneumoniae were collected
each winter. This sample size was powered to detect a 50%
reduction in a 10% carriage rate at 80% power with a 5%
type one error rate. Strains were sequenced at The Well-
come Trust Sanger Institute (WTSI) on Illumina HiSeq with
Truseq chemistry, paired-end (PE), 75 bp (winters 2006/7–
2010/11) and 100 bp (winters 2011/12 2012/13).
Reads were mapped against S. pneumoniae ATCC 700669
using SMALT [12]. The alignment was reduced to variant sites
using SNP-sites [13], subjected to hierarchical Bayesian analy-
sis of population structure (hierBAPS) [14] and overlaid on a
species-wide RAxML [15] phylogeny to define lineages. Sin-
gle-nucleotide polymorphisms (SNPs) were reconstructed on
the phylogeny using the accelerated transformation Sankoff
parsimony method [16]. ARIBAwith the resfinder database was
used to detect acquired resistance determinants [17, 18], and
penicillin binding protein profiles were determined and used
to infer penicillin susceptibility [19] from the fastq files. Line-
age-specific references were used to map against for recombi-
nation analysis. When a published reference was not available,
de novo assemblies were produced using a pipeline at WTSI
utilising Velvet optimiser [20] and SPADES [21] and ordered
against S. pneumoniae ATCC 700669 with ABACAS to pro-
vide a draft reference [22] (Table S1). Metrics r/m and rho/
theta were calculated for each lineage using Gubbins [23]. The
phylogeny, annotated with metadata including accession num-
bers from the European nucleotide database, was uploaded to
permanent microreact URL at: https://microreact.org/project/
Southampton-pneumo-carriage. Significant changes in pro-
portions between two groups were detected using Fisher’s
exact test with two-tailed P-values and adjusted for multiple
comparisons using the R p.adjust fdr method. Correlations
between measures of recombination and the number of sero-
types per lineage, were assessed with the Pearson correlation
coefficient. The P-value reported was derived from the R
score.
RESULTS
The collection of 672 isolates was clustered into 20 BAPS line-
ages and a polyphyletic bin by the primary hierarchical clus-
tering of hierBAPS [14] (Fig. 1). Three lineages (BAPS 1, 10
and 11) were dominated by PCV7 VTs and a further three
(BAPS 4, 13 and 16) by PCV13 VTs together compris-
ing >50% of the isolates collected in the primary winter of this
study, referred to here as the starting population (Fig. 2).
IMPACT STATEMENT
This is the first description of the population structure of
this collection of pneumococcal carriage isolates in the UK.
This study sought to define dominant lineages and their
dynamics over the study period. When a non-vaccine type
(NVT) was detected in a vaccine type (VT) lineage in the
pre-pneumococcal conjugate vaccine (PCV) era, that NVT
was observed to expand, replacing the vaccine serotype. If
it can be predicted which NVT/genotype combinations are
likely to be involved in replacement, the clinical impact can
be assessed, via the lineages antibiotic resistance and viru-
lence determinants profile and the invasive potential of the
serotype expressed. Establishing the population structure
and serotype mixture of lineages in countries thinking
about PCV implementation could therefore offer additional,
geographically specific, information during the PCV selec-
tion process.
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Lineage extinction
The CCs and STs described here are encompassed by the
BAPS lineages, but not equivalent to the broader designa-
tions of BAPS. Lineage BAPS1, which encompasses ST176,
exclusively expressed PCV7 vaccine serotype 6B, and
decreased in prevalence significantly between the primary
winter 2006/7 and post-PCV7 winter 2009/10 before
PCV13 introduction (P<0.0001) after adjusting for multiple
testing (Fig. 2a). The striking decrease in this lineage culmi-
nated in its absence in the final two winters (2011/12 and
2012/13) of this study, with no resurgence of 6B or the STs
encompassed by this lineage in winters 2013/14–2015/16
subsequent to 2012/13 in this ongoing carriage surveillance
study (our unpublished data).
BAPS13, which includes ST65, exclusively expressed PCV13
serotype 6A. BAPS13(6A) increased temporarily after the
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Fig. 1. Population structure of the pneumococcal collection, coloured blocks represent each BAPS lineage or sub-lineage of the bin
with the corresponding branch coloured accordingly. BAPS lineage blocks are labelled internally with the predominant serotype/s
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Fig. 2. VT lineage temporal serotype dynamics, prevalence of serotypes per VT BAPS lineage each winter. Serotype bars are labelled
and coloured based on their respective vaccine inclusion status.
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introduction of PCV7 but decreased soon after the intro-
duction of PCV13. In 2012/13 only one 6A isolate was
detected in this study, and no serotype replacement was
observed for BAPS13(6A) (Fig. 2b). Furthermore, serotype
6A was absent from the carriage study population in subse-
quent winters of 2013/14 and 2015/16 (unpublished data).
Serotypes 6B and 6A were two of the top three serotypes
reported in the primary winter 2006/7 [10]. The majority of
which were encompassed by the two lineages BAPS1(6B)
and BAPS13(6A). These two lineages showed the largest
decreases during the study and both lineages exclusively
expressed their respective serotypes 6B and 6A. BAPS16 [3],
dominated by ST180, exclusively expressed PCV13 VT 3
(Fig. 2c) and also appears to have been nearly removed
from the population, with only one serotype 3 (ST180)
detected between the subsequent winters 2013/14 and 2015/
16 (unpublished data). Significant reductions were not
detected for BAPS13 and BAPS16 (Table S1, available in the
online Supplementary Material), although replacement may
not be complete only 3 years after the introduction of
PCV13 in 2010 [24].
Lineage serotype replacement
The remaining three VT lineages, BAPS4, BAPS10 and
BAPS11, all exhibited serotype replacement, and thus were
maintained in the population. BAPS4, which encompasses
ST199, transitioned from a mixed population of PCV13 VT
19A and NVT 15B/C, to exclusively 15B/C over the seven
winters (Fig. 2d). BAPS10 was initially dominated by PCV7
VT 23F and predominantly ST36. Serotype 23F was
completely replaced by 23B, which was predominantly ST439
(Fig. 2e). In both these instances the replacing serotype was
present in the starting population for that lineage and multiple
STs were involved that previously obscured the replacement
occurring at the lineage level as determined using only MLST
data [3]. The replacing serotypes 15B/C and 23B were among
the top five serotypes by winter 2012/13.
Members of BAPS11 belonging to ST162 initially expressed
VTs 19F and 9V, and decreased significantly after the intro-
duction of PCV7 (P=0.02). However, BAPS11 continued to
persist in the population at a low level with 19F replaced by
multiple different serotypes through the study period
including serogroup 24 [24F (n=2), 24B (n=1)] (Fig. 2f).
Serogroup 24 isolates were not observed within BAPS11 in
the primary winter 2006/7. However, the phylogeny indi-
cates that the BAPS11 serogroup 24 isolates shared a most
recent common ancestor with all 19F strains including those
19Fs present in the starting population. This lineage, specifi-
cally ST162, went on to cause four disease cases post-
PCV13 in the Hampshire region, expressing serotype 24F.
The remaining PCV VTs were detected in small numbers
during the study and do not play a major role in the dynam-
ics of this population structure.
Lineage expansion
Changes in prevalence of NVT lineages BAPS12(11A, CC62)
and BAPS17(15A, CC58) during the study were not
statistically significant (Fig. 1 and Table S1). Significant
increases between winter 2006/7 and 2009/10 for BAPS5(21,
CC193) and BAPS18(22F, CC433) were non-significant after
adjusting for multiple testing. No significant increase was
observed between 2006/7 and 2012/12 for these two lineages.
Individual NVT lineages exhibiting serotype exclusivity in the
pre-PCV period did not expand significantly after PCV intro-
ductions, with no single NVT lineage offsetting the striking
removal of VT lineages like BAPS1(6B) in this sampling.
Antibiotic resistance
Low prevalence and sporadic acquisition of antibiotic resis-
tance determinants were detected in this population. As only
limited antibiotic phenotype data was available for this dataset,
resistance was inferred from the presence of known genetic
determinants of resistance. Work published by Metcalf et al.
allowed us to make inferences of penicillin susceptibility from
the penicillin binding protein allele profiles [25]. The profiles
were used to predict that the isolates have minimum inhibi-
tory concentrations of <0.03 µgml 1, and can be classed as
susceptible to penicillin [19, 25, 26]. Only 16% of isolates had
acquired non-core genes known to confer resistance, 5.5% of
isolates had acquired more than one resistance gene, and only
1% had acquired more than two. The acquired resistance
genes detected, including mef, msrD, tetM and ermB, are typi-
cal for the pneumococcal species, though their prevalence in
this population is low [27]. A phylogenetic cluster of acquired
resistance genes, could be observed for BAPS13(6A), that had
acquired the mefE gene for macrolide resistance. Whilst this
lineage decreased in prevalence during the study, BAPS8(35F/
10A), also containing mefE, temporarily increased and so
maintained the gene within the population. The increase in
BAPS8 was not sustained through the study period, with a
non-significant difference between 2006/7 and 2012/13.
BAPS13(6A, CC65) and BAPS8(35F/10A, CC1635) share a
common ancestor before they share one with any other BAPS
lineage, indicating that their common ancestor was likely to be
mefE-positive. NVT BAPS21(15A) carried tetM and ermB but
its prevalence never exceeded 0.05 in any given year and a sig-
nificant increase was not detected within the study period.
There was no clonal acquired resistance associated with the
lineages being removed from the population, or differences
between the VT and NVT components in lineages that were
replaced, leaving the resistance profile of the lineages and the
population unchanged.
Recombination
Both r/m and rho/theta vary between lineages, in this popu-
lation BAPS lineages with a high recombination to mutation
ratio (r/m), also tended to have a high number of recombi-
nation events to point mutations ratio (rho/theta)
(Table S1). For the majority of lineages r/m was greater
than one and thus recombination introduced more genetic
variation than point mutations. A moderate positive corre-
lation was observed between the number of recombination
events and number of serotypes for each BAPS lineage
R=0.534, P=0.01525 in concordance with the correlation
reported by Croucher et al. [9].
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DISCUSSION
We observed that VT lineages expressing multiple serotypes
in the starting population underwent serotype replacement
and were retained in the carriage population after PCV
introductions. Conversely lineages expressing exclusively
VT serotypes decreased to almost undetectable levels at the
end of the study period. Pneumococcal sequencing has been
employed by numerous research groups to gain further
insight into its biology [28–33]. Only three other studies,
however, have assessed the species-wide population struc-
ture in the context of PCVs [7, 34, 35]. To determine if our
findings in this carriage collection could be extrapolated to
other geographical locations we made a comparison with
the one other study that describes changes in prevalence of
BAPS clusters pre and post PCV7 [7]. The UK collection
reported here has numerous observable similarities to the
pneumococcal carriage population from Massachusetts [7].
The collections have similar numbers of lineages defined by
hierBAPS and include considerable polyphyletic bins of
low-frequency genotypes accounting for 17% (UK) and
20% (Massachusetts). There is considerable overlap when
using STs and CCs as a proxy for comparing BAPS lineages
in the two populations. This approach established which
BAPS lineages were shared for the subsequent comparison.
Four BAPS clusters in Massachusetts expressed PCV7 VTs
in 2001. All four underwent replacement to varying extents.
In Massachusetts BAPS9 (23F), known as sequence cluster
(SC) 9 in the original paper, replacement was observed that
could be expected with our hypothesis given the presence of
23A and 23B in 2001. This mirrored the replacement of
BAPS10(23F), its counterpart in the UK, that encompassed
ST439 and ST3636. Unlike the UK collection, the remaining
three PCV7 VT lineages in Massachusetts were replaced by
NVTs that were not detected in the 2001 sampling. The
Massachusett VT lineages were a much smaller proportion
of the starting population the in the UK (17 and 57%
respectively). It is likely that the NVTs were present in the
population but went unsampled in 2001 [7].
Sample size is critical to properly assess diversity within a
population and to detect changes. A sufficient sample with
enough statistical power can reduce the likelihood of any
minority serotypes/lineages going undetected. Any sampling
designed to establish the population structure could addi-
tionally be complemented with data on serotype and STs
from pubMLST. For example, an isolate from Italy, of
ST162 24F observed in 1998, is reported in the public MLST
database, further indicating that the BAPS11 24F capsular
variant that replaced 19F was generated through capsular
switching pre-PCV and circulating in Europe. Additionally,
BAPS11 did express two unrelated PCV7 VTs (19F, 9V) in
2006/7 from a sample of nine strains. This may indicate that
BAPS11 has a propensity for capsule switching and
serogroup 24 may have been uncovered with deeper sam-
pling. Screening the MLST databases would determine, for a
given lineage, whether any unsampled NVTs have previ-
ously been documented in the same location and time
frame. Although pubMLST may have a bias towards rare
and novel serotype ST combinations. It is possible that a
low-frequency serotype mixture is present in all lineages
and that serotype exclusivity would not be observed with
exhaustive sampling. Constraints on serotype switching is
an area of ongoing investigation which may add insight into
whether capsule switches occur in all lineages [9]. However,
the presence of NVTs in the starting population, even in a
small number of samples, appears to be a strong indication
for subsequent replacement within that lineage. For
resource-limited countries where PCVs are still being intro-
duced via national immunization programs, preliminary
studies on the pre-PCV population structures have been
published [30, 35, 36]. When post-PCV data is available it
will be informative to compare these to the early PCV
adopters in the resource-rich countries of Europe and North
America, especially given the different burden of disease
and serotype prevalence [37].
In addition to the patterns of replacement described, similar
serotype mixes were observed for some lineages in both Mas-
sachusetts and our UK collection. Massachusetts lineage SC8
and its equivalent UK BAPS4 are characterised by CC199.
Both locations included 19A and 15B/C at near equal propor-
tions in these lineages in the initial sampling. After PCV13,
replacement of 19A by 15B/C in this lineage was observed in
both populations despite the geographical distance [38]. Sub-
sequent increases in 15B/C IPD cases were observed in the
UK and USA [6, 39]. The presence of 19A and 15B/C within
the same STs and CCs is also observable in the pneumococcal
pubMLST database involving multiple lineages globally [40].
This indicates that the replacement of 19A by 15B/C post-
PCV could also be anticipated for other countries adopting
PCVs. For this lineage 15B/C has also been shown to be as
equally capable as 19A of causing middle ear infections in
chinchilla [41]. Therefore, 15B/C may be a potential target for
inclusion in future PCVs.
Serotype replacement has been reported across the world [3,
5, 24, 34, 42–46]. Certain serotypes have increased post-
PCV in multiple locations, globally, such as 19A post-PCV7
for disease and carriage [8, 43, 47–49]. However, we and
others have shown that serotype replacement involves
clonal lineages [3, 44, 50–52], therefore it is useful to
consider genotype alongside serotype to understand the
replacement. The extent that different serotypes are
involved in replacement can differ between countries, and is
likely to be directly linked to the prevalence of certain geno-
types in the starting population, with each location having a
unique population structure. For example, the Massachu-
setts lineage SC1(6A) relates to BAPS13(6A). In Massachu-
setts however, SC1 expressed multiple serotypes in the
starting population. This demonstrates that the pattern of
replacement for a given lineage in one country could not
predict whether that replacement will occur for the same
lineage in another. Serotype replacement will be specific to
the starting population in both temporal and spatial terms
and reservoirs at the boundaries of the geographic
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population, for example, differing use of PCVs in neigh-
bouring countries may also need to be considered.
Lineage-specific antibiotic resistance profiles in this UK col-
lection were detected in dominant lineages BAPS8, 13 and
21, potentially contributing to the success of these lineages.
However, with only low-level prevalence of antimicrobial
resistance, it appears not to be essential for the success of
carriage lineages in the UK. While there were reports of
rises in antibiotic resistance in NVTs causing disease after
the introduction of PCV7 in the USA, there was no evidence
of any rise in this UK population [27].
It is of interest to consider both the resistance profile and
serotype makeup of a NVT component of a pre-PCV line-
age with potential to be involved in replacement. In this
case resistance was near absent within the NVTs involved in
replacement and the invasiveness of the NVT capsule, mea-
sured by odds ratios [53, 54], was similar to that of the VTs
they were replacing. It would be of concern if a NVT com-
ponent of a VT lineage had a capsule known to be more
invasive than the VT it could replace, influencing the rate at
which the lineage could translate into disease cases. Further-
more, if the NVT component of a pre-PCV lineage
contained fewer resistance determinants than its VT coun-
terpart, even with the prevalence of the lineage remaining
stable it could, in theory, reduce the contribution of that
lineage to resistance in that population and influence the
ability to treat pneumococcal infections from that lineage.
Genomic surveillance of carriage increasingly has the
advantage of being rapidly deployed for the capture of the
dynamics of pneumococcal population structure over PCV
introductions. A combination of lineage extinction, replace-
ment and expansion of multiple low-frequency genotypes
will contribute to post-PCVs population structure. These
processes combined have resulted in the stable carriage
prevalence observed for this collection over time [3, 4, 10].
Genomic population datasets such as this also lend them-
selves to modelling the impact of PCVs on a given popula-
tion, which may offer greater predictive value for assessing
implementations of PCVs.
Conclusion
Here we give the first description, of the population struc-
ture for this UK carriage collection. This allowed us to
observe that serotype exclusivity within a lineage during the
primary sampling winter was an indicator that the lineage
would go on to be removed from circulation rather than
undergo replacement with unsampled NVTs. Conversely
the presence of multiple serotypes in the starting population
of a VT lineage indicated that the lineage would undergo
serotype replacement following PCV. When a NVT was
sampled in the primary winter this NVT went on to be the
replacing type in this study. There were no significant
expansions of individual NVT lineages in this sampling.
Observed significant increases in NVTs post-PCV are as a
result of the combined NVT replacement through expan-
sion of multiple lineages. As serotype replacement is
influenced by the genotypic background, identifying VT lin-
eages at risk of serotype replacement could additionally
assess the added impact of the antibiotic resistance profile
or virulence determinants such as capsule of the NVT com-
ponent. These observations could be used to inform PCV
selection or future design of extended valency PCVs for a
given population.
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